Back

Oncogenic ERK signaling represses chaperone-mediated autophagy through transcriptional control of LAMP-2A

Berenger, E.; Kacal, M.; Maestri, A.; Kochetkova, E.; Zhang, B.; Sajwan, S.; Mannervik, M.; Norberg, E.; Kaminskyy, V. O.; Vakifahmetoglu Norberg, H.

2026-03-04 cell biology
10.64898/2026.03.03.709259 bioRxiv
Show abstract

Chaperone-mediated autophagy (CMA) is a selective lysosomal degradation pathway governed by the rate-limiting receptor LAMP-2A and increasingly implicated in cancer. However, the oncogenic circuits that enforce CMA repression and whether this state is therapeutically reversible remain unclear. Here, we developed a quantitative bioluminescence-based reporter to measure CMA activity in human cancer cells and combined parallel chemical and genome-scale CRISPR-Cas9 screens to define regulatory pathways. The chemical screen identified GSK1059615 as a CMA-restoring compound that increased LAMP-2A transcription and protein abundance in vitro and in vivo. In parallel, the CRISPR screen revealed ERK signaling as a pathway-level suppressor of CMA. Genetic or pharmacologic ERK inhibition de-repressed LAMP-2A expression, while integrated modulation of ERK, PI3K-AKT, and p38 signaling coordinated transcriptional induction and stabilization of LAMP-2A. Transcriptomic analyses further implicated FOXO1/FOXP1-driven programs in LAMP-2A regulation. Together, these findings position CMA as an integrated output of oncogenic signaling networks and establish a mechanistic framework for restoring CMA activity in defined cancer contexts.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.